Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock After Barclays’ Target Increase?
TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00.
Hims & Hers Health Inc. (HIMS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 6,915,700 | $143,569,932 | +56% | 0.02% | |
| 2. | 4,179,700 | $86,770,572 | -38% | 0.01% | |
| 3. | Renaissance Technologies Jim Simons | 2,118,080 | $43,971,341 | -57% | 0.07% |
| 4. | 1,126,100 | $23,377,836 | -24% | 0.01% | |
| 5. | 1,116,300 | $23,174,388 | +982% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.24 | 48,400 | $1,172,974.00 | 224,417 | 2026-05-26 | Filing | |
| $24.50 | 1,000 | $24,500.00 | 5,000 | 2024-11-14 | Filing | |
| $26.94 | 4,000 | $107,759.60 | 4,000 | 2024-11-12 | Filing | |
| $17.74 | 110,000 | $1,951,763.00 | 110,000 | 2024-05-21 | Filing | |
| $3.66 | 73,700 | $269,742.00 | 125,000 | 2022-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.49 | 7,163 | $261,351.37 | 284,321 | 2026-07-06 | Filing | |
| $35.00 | 23,726 | $830,410.00 | 181,861 | 2026-06-18 | Filing | |
| $34.03 | 18,197 | $619,216.61 | 284,321 | 2026-06-22 | Filing | |
| $31.50 | 14,027 | $441,850.50 | 432,124 | 2026-06-17 | Filing | |
| $31.50 | 4,490 | $141,435.00 | 6,790 | 2026-06-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 80,213 | $2,780,985 | 0.01% | |
| 2. | 52,600 | $1,823,642 | 4.12% | |
| 3. | 45,813 | $1,588,337 | 0.28% | |
| 4. | 33,187 | $1,150,593 | 0.02% | |
| 5. | 9,160 | $317,577 | 0.02% |
News See All
10 Best Weight Loss Drug Stocks to Buy in 2026
The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
10 Stocks Stealing the Spotlight from Wall Street Giants
D-Wave Quantum saw its share prices climb by 12.37 percent on Monday to close at $26.26 apiece, mirroring a wider market optimism, while investors increased their exposure in industries with rosy long...
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen. In this article, we will summarize the bears’ thesis on HIMS.
Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2026 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares.
10 Stocks With Monster Returns
Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, while some favored pharmaceutical players thanks to progress on their pipeline...
Here’s How Cedar Grove Capital Management Benefitted from Its Short Position in Hims & Hers Health (HIMS)
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here.
10 Stocks With Unexpected Gains
Ten stocks kicked off the trading week with significant gains, mirroring Wall Street's broader optimism, as investors cheered strong US jobs data while waiting on the sidelines for developments on the...
7 Best Stocks to Buy for Short Term
In a continuously evolving market, investing has become a game of timing and informed decision-making.
Hedge Fund Resource Center